Pioneering bio-tech company based in Northern Ireland has just released the findingsfrom their official report on the latest clinical studies of an acne treatment using theirground-breaking drug delivery system. The results showed a staggering reduction of acneby up to 95% during a 30 day treatment window.
Belfast, Northern Irealand. SiSaf Ltd has been carrying out a clinical study using Grade II (mild to moderate) and Grade III (moderate to severe) acne patients. The patients were treated over a period of 30 days and results have been conclusive and extremely positive showing reduction of facial acne vulgaris by up to 95%. Announcing the results of this latest clinical study, Dr Suzanne Saffie-Siebert, CEO of SiSaf said: “According to our data, our formulation combines exceptional safety with very high effectiveness. It is gentle on the skin and suitable for Grade I or II patients but it is also strong enough for use by Grade III acne patients, potentially eliminating the need for
systemic therapies. This product has the potential to absolutely revolutionise the lives of people who are suffering with acne and want a safe and effective treatment without fear of harmful or adverse side effects.” Dermatologists grade acne into four categories and this study used patients with Grade II and Grade III acne. Grade II acne is considered as being moderate acne which can be treated with topical over-the-counter products. However Grade III acne is considered severe. The main difference between Grade II acne and Grade III is the amount of inflammation present and Grade III acne normally requires treatment by a dermatologist. Usually, Grade III acne will be treated with both topical and systemic therapies available only by prescription. Left untreated, Grade III acne may progress to Grade IV.